<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; expenditure</title>
	<atom:link href="http://www.tapanray.in/tag/expenditure/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery</title>
		<link>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery</link>
		<comments>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/#comments</comments>
		<pubDate>Mon, 14 Sep 2020 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair drug pricing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[spending]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10259</guid>
		<description><![CDATA[Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health &#8230; <a href="http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing: Why Justify On R&amp;D Cost Rather Than Precise ‘Customer Value’?</title>
		<link>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value</link>
		<comments>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/#comments</comments>
		<pubDate>Mon, 16 Dec 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[connects]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[electronics]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[justification]]></category>
		<category><![CDATA[justify]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monetary]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9815</guid>
		<description><![CDATA[While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&#38;D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for &#8230; <a href="http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Patient Compliance To Boost Pharma Sales…And More…</title>
		<link>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-patient-compliance-to-boost-pharma-salesand-more</link>
		<comments>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/#comments</comments>
		<pubDate>Mon, 20 May 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[drug companies]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[new products]]></category>
		<category><![CDATA[non-adherence]]></category>
		<category><![CDATA[noncompliance]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-compliance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9534</guid>
		<description><![CDATA[One high-impact area in the healthcare space that often finds its place in the backseat is &#8211; patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course &#8230; <a href="http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Affordable Access To Quality Healthcare in India, Invest Where The Mouth Is</title>
		<link>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is</link>
		<comments>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/#comments</comments>
		<pubDate>Mon, 25 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB-NHPS]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Ayushman Bharat Program]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[hospitalization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[invest]]></category>
		<category><![CDATA[Modicare]]></category>
		<category><![CDATA[National Health Protection Scheme]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[where the mouth is]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9454</guid>
		<description><![CDATA[On September 25, 2018, well-hyped Ayushman Bharat &#8211; National Health Protection Scheme (AB-NHPS), touted as the largest health scheme in the world, was launched in India. Prior to its launch, while announcing the scheme on August 15, 2018 from the &#8230; <a href="http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-affordable-access-to-quality-healthcare-in-india-invest-where-the-mouth-is/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will AB-NHPM Mitigate Indian Healthcare Crisis?</title>
		<link>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-ab-nhpm-mitigate-indian-healthcare-crisis</link>
		<comments>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/#comments</comments>
		<pubDate>Mon, 18 Jun 2018 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Ayusman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inpatient]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHFS]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NHPM]]></category>
		<category><![CDATA[NHRM]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outpatient]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RSBY]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tertiary]]></category>
		<category><![CDATA[transportation]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9039</guid>
		<description><![CDATA[Since long, hypes have created on several healthcare schemes in India, by the successive Governments of different political dispensation. These attracted mostly positive vibes at the time of announcements. Nevertheless, as we move on, a vast majority of Indians continues &#8230; <a href="http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Pricing Pressure to Escalate Further?</title>
		<link>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-pressure-to-escalate-further</link>
		<comments>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/#comments</comments>
		<pubDate>Mon, 12 Feb 2018 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[Central Medical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[escalate]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Progressive India” report]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[“Healthy States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8849</guid>
		<description><![CDATA[On February 09, 2018, NITI Aayog released its “Healthy States, Progressive India” Report. The study ranked the States based on ‘health index’. Kerala, Punjab and Tamil Nadu featured as top three in terms of overall performance in 2015-16. However, the interstate variation &#8230; <a href="http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-pressure-to-escalate-further/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health Care: &#8220;India Has Moved From Strength To Strength!”</title>
		<link>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=health-care-india-has-moved-from-strength-to-strength</link>
		<comments>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/#comments</comments>
		<pubDate>Mon, 02 Nov 2015 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bangladesh]]></category>
		<category><![CDATA[Bhutan]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[child]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Editor-in- Chief]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[gandhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Horton]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indicators]]></category>
		<category><![CDATA[Maldives]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Maneka]]></category>
		<category><![CDATA[meal]]></category>
		<category><![CDATA[mid-day]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[moved]]></category>
		<category><![CDATA[Nepal]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[The Lancet]]></category>
		<category><![CDATA[Vietnam]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7227</guid>
		<description><![CDATA[The above flabbergasting assertion came recently from the Union Government of India in context of current health care system in the country.  To be specific, this proclamation of the Ministry of Health was reportedly made at its ‘point by point &#8230; <a href="http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does The Attempt To ‘Debunk Five Big Myths About Big Pharma’ Not Reconfirm The Truth?</title>
		<link>http://www.tapanray.in/does-the-attempt-to-debunk-five-big-myths-about-big-pharma-not-reconfirm-the-truth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-attempt-to-debunk-five-big-myths-about-big-pharma-not-reconfirm-the-truth</link>
		<comments>http://www.tapanray.in/does-the-attempt-to-debunk-five-big-myths-about-big-pharma-not-reconfirm-the-truth/#comments</comments>
		<pubDate>Mon, 22 Jun 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Big Myths]]></category>
		<category><![CDATA[Big Pharma]]></category>
		<category><![CDATA[Debunk]]></category>
		<category><![CDATA[Debunk Five Big Myths About Big Pharma]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[five]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[John Lechleiter]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6754</guid>
		<description><![CDATA[Late last week while returning to India, to my pleasant surprise, I bumped into a longtime overseas friend and his wife working in the pharma industry. Incidentally, they were also traveling in the same flight with a plan to spend &#8230; <a href="http://www.tapanray.in/does-the-attempt-to-debunk-five-big-myths-about-big-pharma-not-reconfirm-the-truth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-attempt-to-debunk-five-big-myths-about-big-pharma-not-reconfirm-the-truth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Frugal Public Resource Allocation Quo Vadis Healthcare in India?</title>
		<link>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india</link>
		<comments>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 16 Mar 2015 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[14th]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[erstwhile]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[frugalNational]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Policy 2015]]></category>
		<category><![CDATA[quo vadis]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6448</guid>
		<description><![CDATA[The memory is still afresh in India. A new political dispensation took charge of the governance of the country, riding on the tidal waves of people’s hope and aspirations, with presumed credibility to ‘Walk the Talk’. The expectations were skyrocketing &#8230; <a href="http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
